TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00853294
Drug: Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
Normalized name: chlorpheniramine polistirex / hydrocodone polistirex Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
Study: NCT00853294
Drug: 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
Study: NCT00518544
Drug: administration of hydroxyehtyl starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: colloid is administered during operation according to blood loss.
Study: NCT03022253
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
Study: NCT01262677
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched to the active drug
Study: NCT00607685
Drug: 5 Fluorouracil with hyaluronic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
Study: NCT01016678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy pill comparator
Study: NCT01212263
Drug: Step-up HP u FSH
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
Study: NCT00615602
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
Study: NCT00615602
Drug: 5-fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
Study: NCT03491969
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, po, tid
Study: NCT00153881
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles).
Study: NCT02508220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: distilled water in nasal spray
Study: NCT02707601
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
Study: NCT02707601
Drug: F/R/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/25/25 mg FDC tablet administered orally once daily
Study: NCT01171807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P
Study: NCT04294953
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
Study: NCT04063475
Drug: cyanoacrylate tissue adhesive beside sutures
Normalized name: ethyl cyanoacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: using cyanoacrylate tissue adhesive for FGG fixation
Study: NCT02707601
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT04687059
Drug: Placebo Option 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for injection
Study: NCT04687059
Drug: Placebo Option 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection
Study: NCT02486276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study: NCT02969239
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bolus administered norepinephrine 5mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
Study: NCT04084184
Drug: HGP1602
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10mg
Study: NCT01901341
Drug: CB-5945
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01901341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04398290
Drug: Inhaled nitric oxide (iNO)
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour
Study: NCT00869869
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
Study: NCT00869869
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03585270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
Study: NCT01021397
Drug: rHPIV3cp45
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10\^5 TCID50 nasal drops
Study: NCT01021397
Drug: rHPIV3cp45 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1X-L15 nasal drops
Study: NCT03588130
Drug: EscharEx (5% EX-02 formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active arm
Study: NCT03588130
Drug: Non-surgical standard of care (NSSOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Santyl (Enzymatic debridement) or commercially approved Hydrogel
Study: NCT03167242
Drug: KAF156
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
Study: NCT01487083
Drug: Pomaglumetad methionil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04477369
Drug: DWJ1439
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg single dose
Study: NCT04477369
Drug: DWJ1464
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg single dose
Study: NCT04477369
Drug: DWC202003
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg single dose
Study: NCT04477369
Drug: DWC202004
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg single dose
Study: NCT00467142
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02929329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT02929329
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
Study: NCT00621101
Drug: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Study: NCT00621101
Drug: 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
Study: NCT00467142
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03351361
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
Study: NCT05153278
Drug: Intravenous drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment for iron deficiency treatment
Study: NCT00703937
Drug: Standard Medical Care (SMC) for the treatment of IDA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01033422
Drug: CF101
Normalized name: CF101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
Study: NCT01033422
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets orally every 12 hours for 16 weeks
Study: NCT03368339
Drug: PR013 (0.045%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR013 topical Ophthalmic Drops (0.045%)
Study: NCT03368339
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT03160040
Drug: Minocycline IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
Study: NCT01066520
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 g, 3 times daily topical during 14 days
Study: NCT01154036
Drug: Comparator: rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00926965
Drug: Conventional antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
Study: NCT01375959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 placebo capsules orally twice a day for 6 weeks
Study: NCT02947087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
Study: NCT02435121
Drug: SAR125844
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Concentrate for solution Route of administration: intravenous
Study: NCT01253304
Drug: LY2189265
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT01327495
Drug: Testosterone 1% gel 1.25 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Study: NCT01327495
Drug: Testosterone 1% gel 2.5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Study: NCT01327495
Drug: Testosterone 1% gel 5.0 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Study: NCT01327495
Drug: testosterone 1% gel 15 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Study: NCT01503385
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
Study: NCT00307684
Drug: double blind placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets once daily for 4 weeks
Study: NCT00005108
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006011
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03492944
Drug: Ultrasound Microbubble Contrast Agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
Study: NCT01639560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
Study: NCT01001338
Drug: RDEA594
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uricosuric agent for the treatment of gout.
Study: NCT01001338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01160289
Drug: LY2452473
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily for 12 weeks
Study: NCT01160289
Drug: placebo (tadalafil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily for 12 weeks
Study: NCT01160289
Drug: placebo (LY2452473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally, once daily for 12 weeks
Study: NCT01393145
Drug: Seretide Diskus (salmeterol/fluticasone) 50/250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
Study: NCT01090180
Drug: Placebo (sugar pill)
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive
Study: NCT04458675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A biodegradable capsule, which visually similar to the Vibrant active capsule
Study: NCT02875886
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined with hydrochlorothiazide
Study: NCT01015547
Drug: Methotrexate alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Study: NCT01876108
Drug: H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
Study: NCT04470973
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive amikacin as part of standard care.
Study: NCT01201642
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
Study: NCT05596071
Drug: Sufentanil Citrate
Normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
Study: NCT01452373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
Study: NCT01247285
Drug: Fluoxetine Hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg Capsules
Study: NCT01247285
Drug: PROZAC WEEKLY®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg Capsules
Study: NCT01884948
Drug: Omegaven™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00944515
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet or syrup 3 days/week
Study: NCT00944515
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin 3 days/week
Study: NCT00254046
Drug: TMC125
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X100 mg tablets b.i.d.96 weeks
Study: NCT00254046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets b.i.d.96 weeks
Study: NCT03908957
Drug: Ga68-Dolacga Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
Study: NCT00858364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously once every 3 weeks
Study: NCT01710020
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 10 mg oral powder for constitution
Study: NCT02984982
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02984982
Drug: Antiplatelets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Study: NCT02984982
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral
Study: NCT04716335
Drug: Placebo (Harmine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Harmine
Study: NCT04061044
Drug: Ophthalmic Insert
Normalized name: OPHTHALMIC INSERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost, 0.32 mg
Study: NCT02615002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01917279
Drug: Docetaxel plus Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration.~For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
Study: NCT01917279
Drug: Intermittent Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
Study: NCT01917279
Drug: Metronomic Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
Study: NCT01823939
Drug: iOWH032
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032.
Study: NCT02524054
Drug: Aerosolized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
Study: NCT00006015
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
Study: NCT00006015
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
Study: NCT00781053
Drug: P144 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
Study: NCT00866905
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
Study: NCT03026946
Drug: Alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
Study: NCT00948766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
Study: NCT00203801
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00683423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
Study: NCT00537654
Drug: Treatment sequence A
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
Study: NCT00537654
Drug: Treatment sequence B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
Study: NCT00537654
Drug: Treatment sequence C
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
Study: NCT00537654
Drug: Treatment sequence D
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state